MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes

Oncogene

Volumn 34, Issue 37, 2015, Pages 4867-4878

  Keklikoglou, I ^a,b   Hosaka, K ^c   Bender, C ^a   Bott, A ^a   Koerner, C ^a   Mitra, D ^a   Will, R ^a   Woerner, A ^a   Muenstermann, E ^a   Wilhelm, H ^a   Cao, Y ^c,d,e   Wiemann, S ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b EPFL   (Switzerland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; K RAS PROTEIN; LIPOCORTIN 2; MICRORNA; MICRORNA 206; MONOCYTE CHEMOTACTIC PROTEIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN A; VASCULOTROPIN C; ANXA2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; MIRN206 MICRORNA, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PANCREATIC TISSUE; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; ADENOCARCINOMA; ANIMAL; CELL CULTURE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR INVASION; UMBILICAL VEIN ENDOTHELIAL CELL;

ADENOCARCINOMA; ANIMALS; ANNEXIN A2; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; CELLS, CULTURED; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHANGIOGENESIS; MICE; MICE, SCID; MICRORNAS; NEOPLASM INVASIVENESS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84941314443     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.408     Document Type: Article

References (47)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Tuveson DA, Hingorani SR. Ductal pancreatic cancer in humans and mice. Cold Spring Harb Symp Quant Biol 2005; 70: 65-72.
3. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-465.
4. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-450.
5. Aguirre AJ, Bardeesy N, Sinha M, Lopez L, Tuveson DA, Horner J et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003; 17: 3112-3126.
6. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kappaB-cytokine network. Cancer Discov 2011; 1: 158-169.
7. Wang W, Abbruzzese JL, EVans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factorkappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5: 119-127.
8. Arlt A, Gehrz A, Muerkoster S, Vorndamm J, Kruse ML, Folsch UR et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003; 22: 3243-3251.
9. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9: 346-354.
10. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 105-120.
11. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
12. du Rieu MC, Torrisani J, Selves J, Al Saati T, Souque A, Dufresne M et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 2010; 56: 603-612.
13. Munding JB, Adai AT, Maghnouj A, Urbanik A, Zollner H, Liffers ST et al. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 2012; 131: E86-E95.
14. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene 2012; 31: 4150-4163.
15. Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH et al. Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012; 18: 1352-1363.
16. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res 2012; 40: 3689-3703.
17. Taulli R, Bersani F, Foglizzo V, Linari A, Vigna E, Ladanyi M et al. The musclespecific microRNA miR-206 blocks human rhabdomyosarcoma growth in xenotransplanted mice by promoting myogenic differentiation. J Clin Invest 2009; 119: 2366-2378.
18. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147-152.
19. Liou GY, Doppler H, Necela B, Krishna M, Crawford HC, Raimondo M et al. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappaB and MMPs. J Cell Biol 2013; 202: 563-577.
20. Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V et al. K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PloS One 2012; 7: e44146.
21. Sarkar S, Swiercz R, Kantara C, Hajjar KA, Singh P. Annexin A2 mediates upregulation of NF-kappaB, beta-catenin, and stem cell in response to progastrin in mice and HEK-293 cells. Gastroenterology 2011; 140: 583-95 e4.
22. Zhang G, Schetter A, He P, Funamizu N, Gaedcke J, Ghadimi BM et al. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma. PloS One 2012; 7: e31507.
23. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007; 67: 2098-2106.
24. Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PloS One 2011; 6: e19390.
25. Brownstein C, Deora AB, Jacovina AT, Weintraub R, Gertler M, Khan KM et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages. Blood 2004; 103: 317-324.
26. Madureira PA, Surette AP, Phipps KD, Taboski MA, Miller VA, Waisman DM. The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood 2011; 118: 4789-4797.
27. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004; 172: 2853-2860.
28. Matsuo Y, Raimondo M, Woodward TA, Wallace MB, Gill KR, Tong Z et al. CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 2009; 125: 1027-1037.
29. Miyake M, Goodison S, Urquidi V, Gomes Giacoia E, Rosser CJ. Expression of CXCL1 in human endothelial cells induces angiogenesis through the CXCR2 receptor and the ERK1/2 and EGF pathways. Lab Invest 2013; 93: 768-778.
30. Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 2006; 203: 941-951.
31. Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ et al. Granulocyte-and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 1989; 337: 471-473.
32. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 2012; 21: 836-847.
33. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409-421.
34. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol 2000; 2: 737-744.
35. Stamatovic SM, Keep RF, Mostarica-Stojkovic M, Andjelkovic AV. CCL2 regulates angiogenesis via activation of Ets-1 transcription factor. J Immunol 2006; 177: 2651-2661.
36. Low-Marchelli JM, Ardi VC, Vizcarra EA, Van Rooijen N, Quigley JP, Yang J. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res 2013; 73: 662-671.
37. Stahlhut C, Suarez Y, Lu J, Mishima Y, Giraldez AJ. miR-1 and miR-206 regulate angiogenesis by modulating VegfA expression in zebrafish. Development 2012; 139: 4356-4364.
38. Cao R, Ji H, Feng N, Zhang Y, Yang X, Andersson P et al. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci USA 2012; 109: 15894-15899.
39. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-198.
40. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140: 460-476.
41. Cao Y. Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005; 5: 735-743.
42. Sharma M, Blackman MR, Sharma MC. Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model. Exp Mol Pathol 2012; 92: 175-184.
43. Wang CY, Chen CL, Tseng YL, Fang YT, Lin YS, Su WC et al. Annexin A2 silencing induces G2 arrest of non-small cell lung cancer cells through p53-dependent and-independent mechanisms. J Biol Chem 2012; 287: 32512-32524.
44. Seckinger A, Meissner T, Moreaux J, Depeweg D, Hillengass J, Hose K et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 2012; 120: 1087-1094.
45. Stupack DG, Cheresh DA. ECM remodeling regulates angiogenesis: endothelial integrins look for new ligands. Sci STKE 2002; 2002: pe7.
46. Singh A, Happel C, Manna SK, Acquaah-Mensah G, Carrerero J, Kumar S et al. Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis. J Clin Invest 2013; 123: 2921-2934.
47. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.